AGR2 and breast carcinoma: Consistently, the knockdown of AGR2 in the MCF7 and T47D breast cancer cell lines reduced the fulvestrant treatment resistance in both cell lines, whereas the overexpression of AGR2 in the MCF7 cells increased cell survival under the fulvestrant treatment [16].